I decided to ignore Italy in the analysis because of incomplete details, and wait for confirmed results. You are correct that it could easily be comparable to NHS. The ex-dividend shares are at least fairly priced now at $.09, assuming the outlook is credible. The new shares will probably be introduced this fall, after some good news. If Jonathan is less ebullient and more comprehensive in his announcements, my confidence will be bolstered.
Thank you for your comment.